Prostamax vs PT-141 (Bremelanotide)
A side-by-side research comparison of Prostamax and PT-141 (Bremelanotide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Prostamax | PT-141 (Bremelanotide) |
|---|---|---|
| Full name | Prostamax (Prostate Peptide Bioregulator) | Bremelanotide (PT-141 / Vyleesi) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound (peptide bioregulator) | FDA Approved |
| Mechanism | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. |
| Molecular weight | ~ (short peptide) | 1,025 Da |
| Half-life | Short (peptide) | 2.7 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (SubQ) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1.75 mg |
| Frequency | Once daily | As needed, ~45 min before activity |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Related comparisons
Research and educational reference only. Not medical advice.